The combination of recipient and donor KIR-HLA genotypes is worthy of attention as an option to enhance the therapeutic capacity of NK-cell-based immunotherapy in HCC recipients receiving liver transplantation. This evidence concerns the gene KIR3DL1 and hepatocellular carcinoma.